Spots Global Cancer Trial Database for Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Official Title: General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"
Study ID: NCT05100069
Conditions
Interventions
Study Description
Brief Summary: This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Takeda Selected Site, Tokyo, , Japan
Contact Details
Name: Study Director
Affiliation: Takeda
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
